Nykode Therapeutics Advances AI-Powered Immunotherapy Platform with Strong Clinical Progress
核心洞察
Nykode Therapeutics showcased its proprietary AI and machine learning platform for multi-antigen immunotherapy optimization at the BioPharma Drug Discovery Nexus conference in Zurich.
The company's lead asset abi-suva (搜索) demonstrated a 39% objective response rate when combined with KEYTRUDA, compared to 19% for KEYTRUDA alone in the VB-C-03 trial.
Nykode dosed the first patient in its phase II Abili-T trial for HPV+ head and neck cancer (搜索) in May 2026, with interim analysis expected in 2027.
Nykode Therapeutics ASA (OSE: NYKD) presented its advanced artificial intelligence capabilities for immunotherapy design at the 25th BioPharma Drug Discovery Nexus conference in Zurich on April 30, 2026, while reporting significant clinical progress across its pipeline and maintaining a robust financial position.
AI-Driven Drug Discovery Platform
The clinical-stage biopharmaceutical company delivered a presentation titled "From Precision to Performance: AI-Powered Strategies for Optimal Immunotherapies Design," highlighting how it leverages AI and machine learning to accelerate immunotherapy discovery. The company's proprietary platform includes predictive design modeling that enables scientists to model the impact of immunotherapy design choices on protein integrity, folding, and cellular secretion prior to laboratory experimentation, materially reducing time and resource requirements in early-stage discovery.
Nykode's machine learning models support the simultaneous evaluation of thousands of multi-antigen immunotherapy constructs, systematically prioritizing candidate designs against defined criteria for immunogenicity and biophysical properties. The company emphasizes interpretable AI, developing proprietary models alongside interpretable models that enable scientists to understand the molecular features driving optimal design selection.
"At Nykode, applying AI to immunotherapy design is not new as it has been central to how we have built and refined our platform for years," said Michael Engsig, Chief Executive Officer at Nykode Therapeutics. "Our machine learning models allow us to make smarter, faster decisions about which immunotherapy candidates to advance and, crucially, our scientists understand and trust the outputs because interpretability is built into our approach from the start."
Clinical Pipeline Advances
The company's lead product candidate, abi-suva (搜索), a therapeutic immunotherapy for HPV16 (搜索) induced malignancies, achieved significant milestones in Q1 2026. Interim data from the VB-C-03 trial showed a 39% objective response rate for abi-suva plus KEYTRUDA, compared to 19% for KEYTRUDA alone. This data was presented at major conferences, demonstrating the potential of Nykode's APC-targeted technology.
In May 2026, Nykode dosed the first patient in its phase II Abili-T trial for HPV+ head and neck cancer (搜索), with regulatory approvals secured in up to eight European countries. The randomized trial is expected to deliver interim results in 2027, representing a critical milestone for the company's lead asset.
Expanding Platform Applications
Beyond oncology, Nykode is utilizing its APC-targeted technology to create an immune tolerance platform for potential use in autoimmune disorders (搜索), organ transplant rejections, anti-drug antibody reactions, and allergies. The autoimmune disease platform demonstrated immune modulation in human cells and robust preclinical efficacy, advancing toward clinical readiness.
VB10.NEO (搜索), the company's individualized cancer neoantigen immunotherapy, has been investigated in two trials across more than 10 different indications, showcasing the versatility of Nykode's platform technology.
Financial Position and Outlook
Nykode reported a net loss of $4.1 million for Q1 2026, compared to $1.4 million loss in Q1 2025. Cash and cash equivalents at quarter-end totaled $51.3 million, with the company maintaining a strong equity ratio of 93% and total equity of $87.5 million as of March 31, 2026.
Operating expenses decreased to $6.8 million from $7.7 million year-over-year, while net cash outflow from operations was $9.6 million, slightly improved from $10.4 million in Q1 2025. The company's cash runway extends into 2028, potentially 2029 pending a positive tax case outcome, supporting key milestones and ongoing trials.
The company operates under a "human-on-the-loop" philosophy, where AI serves to augment rather than replace scientific expertise, with qualified oversight embedded throughout the discovery and development process. This approach distinguishes Nykode's AI-driven discovery process and supports its continued advancement in the competitive immunotherapy landscape.